Rivastigmine Tartrate Capsule
Product Images NDC 71209-013

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 71209-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cadila Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Rivastigmine Spl Fig1)

A line graph depicting mean change from baseline in ADAS-cog rating over 26 weeks during treatment. The graph compares three groups: 6-12 mg, 1-4 mg, and placebo, showing trends of clinical improvement or decline over time.*

FDA Label Image

Fig2 (Rivastigmine Spl Fig2)

A cumulative percentage plot comparing change from baseline in ADAS-cog scores among patients treated with Rivastigmine Tartrate at 6-12 mg, 1-4 mg, and placebo groups. The X-axis shows change from baseline, while the Y-axis shows cumulative percentage of patients. The graph includes markers indicating 7 points, 4 points improvement, and no change, with an inset table summarizing score changes for each treatment group.*

FDA Label Image

Fig3 (Rivastigmine Spl Fig3)

A bar chart illustrating CIBIC-Plus rating categories versus the percentage of patients. The categories range from Markedly Improved to Markedly Worse, with separate bars comparing Placebo, 1-4 mg, and 6-12 mg treatment groups across these ratings.*

FDA Label Image

Fig4 (Rivastigmine Spl Fig4)

A line graph depicting mean change from baseline in ADAS-cog Rating over 26 weeks of treatment, comparing three groups: 6-12 mg, 1-4 mg, and placebo. The vertical axis shows clinical improvement and decline, and the horizontal axis shows weeks during treatment. Data points include error bars representing standard error of the mean.*

FDA Label Image

Fig5 (Rivastigmine Spl Fig5)

A cumulative percentage plot showing change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares three treatment groups: 6-12 mg, 1-4 mg, and placebo. A table inset presents changes in ADAS-cog scores for each group, detailing treatment effects at various points.*

FDA Label Image

Fig6 (Rivastigmine Spl Fig6)

A bar chart depicting the percentage of patients classified by CIBIC-Plus rating categories, comparing three groups: Placebo, 1-4 mg, and 6-12 mg. The categories range from Markedly Improved to Markedly Worse, showing the distribution of patient responses across these outcomes.*

FDA Label Image

Fig7 (Rivastigmine Spl Fig7)

A line graph showing clinical effect over 24 weeks during treatment, comparing Exelon (rivastigmine) to placebo. The y-axis represents mean change from baseline in ADAS-Cog rating, indicating clinical improvement or decline. Exelon shows increasing improvement up to 16 weeks, while placebo remains near baseline or declines.*

FDA Label Image

Fig8 (Rivastigmine Spl Fig8)

A bar chart comparing the percentage of patients across different ADCS-CGIC rating categories between Exelon and Placebo groups. The categories range from Markedly Improved to Markedly Worse, showing varying percentages for each treatment group.*

FDA Label Image

Rivastigmine-spl-label-60cap-1-5mg (Rivastigmine Spl Label 60cap 1 5mg)

Rivastigmine Tartrate Capsules USP 1.5 mg label showing a white background with pink and black curved design elements. The label states the product is Rx only, contains 60 capsules, and is manufactured by Cadila Pharmaceuticals Ltd. Dosage, storage instructions, and a barcode are also visible.*

FDA Label Image

Rivastigmine-spl-label-60cap-3mg (Rivastigmine Spl Label 60cap 3mg)

Label for Rivastigmine Tartrate Capsules USP, 3 mg strength, displaying product name, dosage strength in a purple box, and quantity of 60 capsules. The label includes storage instructions, manufacturer information for Cadila Pharmaceuticals Limited in Gujarat, India, and a barcode with the NDC 71209-013-03. Marked Rx only, with a note on dosage referencing prescribing information.*

FDA Label Image

Rivastigmine-spl-label-60cap-4-5mg (Rivastigmine Spl Label 60cap 4 5mg)

Rivastigmine Tartrate Capsules USP 4.5 mg label showing dosage strength and capsule count of 60. The label indicates Rx only and includes the manufacturer name Cadila Pharmaceuticals Ltd. Storage instructions specify 25°C with permitted excursions. The label also includes a barcode and a note on serialized datamatrix coding area.*

FDA Label Image

Rivastigmine-spl-label-60cap-6mg (Rivastigmine Spl Label 60cap 6mg)

Label for Rivastigmine Tartrate Capsules USP, 6 mg strength, containing 60 capsules. The label includes dosage form as capsules, prescription-only status, and storage instructions. It states the product is manufactured by Cadila Pharmaceuticals Limited, Ahmedabad, Gujarat, India. The label also shows the NDC number 71209-015-03 and features a barcode and space for serialized datamatrix coding.*

FDA Label Image

Str (Rivastigmine Spl Structure)

Chemical structure of rivastigmine tartrate showing its molecular components, including aromatic rings and functional groups, alongside its tartrate component (C4H6O6).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.